COMP <GO>
SPRY vs AVIR // EV/EBITDA & P/E VALUATION
ARS Pharmaceuticals Inc. (NASDAQ) VS. Atea Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: SPRY 1
— AVIR 2
■ METRIC PARITY
LAST: $3.05 (-9.76%) • MKT CAP: $336.1M
valuation
—
LAST: $4.10 (-0.24%) • MKT CAP: $329.6M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SPRY VS. AVIR)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | SPRY | AVIR | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | -60.00% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | -60.00% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | -5.50% | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 2/9 | 3/9 | -1.00 | AVIR | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 34.1 | 36.0 | -1.90 | AVIR | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $336.1M | $329.6M | $6.5M | SPRY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | SPRY REV | AVIR REV | SPRY GROSS % | AVIR GROSS % | SPRY FCF | AVIR FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $84.3M | $506.5M | — | — | -$171.2M | -$132.0M |
| FY 2024 | $89.1M | $540.3M | — | — | $13.0M | -$135.5M |
| FY 2023 | $30.0K | $459.7M | — | — | -$59.3M | -$85.4M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SPRY // BETA —
AVIR // BETA —